10x Genomics (TXG) EBT (2018 - 2026)

10x Genomics has disclosed EBT across 9 years of filings, most recently posting -$12.8 million for Q1 2026.

• EBT for Q1 2026 came in at -$12.8 million, up 61.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.2 million (up 87.45% YoY), and the FY2025 annual result was -$39.9 million, up 77.54% from the prior year.
• EBT came in at -$12.8 million for Q1 2026 at 10x Genomics, up from -$15.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $37.0 million in Q2 2025 to a low of -$91.7 million in Q3 2023.
• The 5-year median for EBT is -$40.0 million (2022), against an average of -$37.7 million.
• Across the five-year window, EBT slumped 541.0% in 2022 and jumped 199.78% in 2025, its largest moves.
• 10x Genomics' EBT stood at -$16.4 million in 2022, then tumbled by 183.94% to -$46.6 million in 2023, then retreated by 3.82% to -$48.4 million in 2024, then jumped by 68.6% to -$15.2 million in 2025, then climbed by 15.44% to -$12.8 million in 2026.
• The last three EBT figures came in at -$12.8 million (Q1 2026), -$15.2 million (Q4 2025), and -$28.2 million (Q3 2025), per Business Quant data.